Since the first CAR T-cells were described nearly 20 years ago [1], the research field has grown significantly and was accelerated by the FDA approval in 2017 of the anti-CD19 CAR T-cell therapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) [2,3,4]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.